The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.
about
Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?Statin therapy may influence the incidence of postoperative atrial fibrillation: what is the evidence?Statin Therapy for Primary Prevention of Atrial Fibrillation: Guided by CHADS2/CHA2DS2VASc Score.N-Acetylcysteine supplementation for the prevention of atrial fibrillation after cardiac surgery: a meta-analysis of eight randomized controlled trialsStatin therapy for the prevention of atrial fibrillation trial (SToP AF trial)Effect of rosuvastatin on atrial structural remodeling in rabbits with myocardial infarction.Pleiotropic effects of the HMG-CoA reductase inhibitorsUse of serum C-reactive protein as an early marker of inflammatory activity in canine type II immune-mediated polyarthritis: case report.Carvedilol for prevention of atrial fibrillation after cardiac surgery: a meta-analysis.Oxidative stress markers are associated with persistent atrial fibrillationLipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction.Post-operative atrial fibrillation: a maze of mechanisms.High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial.Case report: supraventricular arrhythmia after exposure to concentrated ambient air pollution particlesAtorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein LevelsAtrial fibrillation and the hypercoagulable state: from basic science to clinical practice.Drug therapy for atrial fibrillation: where do we go from here?Is atrial fibrillation an inflammatory disorder?Relationships of High-sensitive C-reactive Protein and P-wave Dispersion in Lone Atrial Fibrillation.Assessment of the Risk Factors and Outcomes for Postoperative Atrial Fibrillation Patients Undergoing Isolated Coronary Artery Bypass Grafting.Modulation of both activator protein-1 and nuclear factor-kappa B signal transduction of human T cells by amiodaroneSignal Transducer and Activator of Transcription 3/MicroRNA-21 Feedback Loop Contributes to Atrial Fibrillation by Promoting Atrial Fibrosis in a Rat Sterile Pericarditis ModelPharmacotherapy of atrial fibrillation: an old option with new possibilities.Pleiotropic effects of statins in atrial fibrillation patients: the evidence.Information learned from animal models of atrial fibrillation.Structural and Functional Remodeling of the Left Atrium: Clinical and Therapeutic Implications for Atrial Fibrillation.Upstream therapy of atrial fibrillation.Targets for immunomodulation in cardiovascular disease--where are we now?Future directions in antiarrhythmic drug therapy for atrial fibrillation.Animal models for atrial fibrillation: clinical insights and scientific opportunities.Significant Increase in C-Reactive Protein and Serum Amyloid A in the Early Hours of Paroxysmal Atrial Fibrillation.Atrial fibrillation and bisphosphonate therapy.Cholesterol and cardiac arrhythmias.Atrial fibrillation and inflammation.Mechanisms of termination and prevention of atrial fibrillation by drug therapy.Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.Mechanisms of new-onset atrial fibrillation complicating acute coronary syndrome.Perspectives and challenges of antioxidant therapy for atrial fibrillation.Atrial Remodeling And Atrial Fibrillation: Mechanistic Interactions And Clinical Implications.Primary Prevention of Atrial Fibrillation where are we in 2012?
P2860
Q24804153-3AF6B063-DEE4-4A85-BD45-7013BBA2C7B2Q33572627-A651DB2D-5EAB-4A9C-95F8-E697981C0176Q33984012-7EBB05F9-8F82-48DD-A100-0D60901F05B9Q34171904-39F34DB8-6EFD-4802-B4A9-0440CE5B0FFBQ34500520-3B313AAA-A5E3-4083-B908-EE8AA71A8534Q34607449-54CC5A67-C9B4-4502-9490-64F71423A575Q34894749-8CB09A7F-BD94-4530-8B21-BD69D74FE659Q35005634-572800CF-F02C-49B9-91C3-C7A0851A67C1Q35140525-E5755ABA-41A6-4860-BC8B-1D379D406D1DQ35172334-49AF529C-1679-4686-AE64-6675C2D99547Q35187745-5A3A6CD6-7CCE-4080-8F24-5B54A5722189Q35684027-BB9DC819-62F6-4277-82A2-A34FC4B62D86Q35756480-C151F67E-988C-454D-94D5-345D54565A68Q35756849-F37C6542-1A29-4998-8995-65E976C954C0Q35851578-D544B382-065B-4D22-8EF4-0711A7D84962Q36030428-A7B475E5-AE22-4EFD-A027-ADEFA2B46B75Q36303805-0BB146A9-018D-49FD-B0E6-9219D51873A6Q36309624-192C3DB5-5C1C-45D8-BBF1-C0C24D9DDF68Q36523303-A5C3AFB3-C5ED-485E-BB90-B48ED4590666Q36721211-9069EE99-D8DC-44F8-9F93-0CD717C5961BQ37070963-4EFDEFB9-8EDB-45ED-8035-86E13EC28B9EQ37116392-CF1843B6-4A82-4F88-96FC-2756860F37C0Q37123391-CD40756C-0DB5-4CE7-8248-D70749CE106AQ37248230-C5DA6889-7E39-4523-9D93-E55C824AB8DFQ37359211-3AA7ADE8-63E1-4433-8D16-06CFEFB8CACFQ37496071-813208AA-51CB-42A9-939B-232E2070D102Q37546133-3F2790FB-436E-4854-A94D-B4EAB916A60AQ37608525-CD669740-5BD9-4BEF-9FDA-4EF10479AA73Q37608547-07075244-2CA6-43CA-965F-827A6D5E1936Q37624219-684CAE17-926B-4AD3-BA11-53B73FFBB778Q37629202-C14EC910-C057-4718-96B2-279CFD4B7078Q37679127-F4B4D6A1-B72D-4A02-98CC-EDFE501417A9Q37770110-DF6233B3-9CFD-441D-B041-BFC66EB8D066Q37821236-B57A243E-A443-41EA-83F2-A2D148ADF168Q37844891-C74135FD-DDE9-40F2-A903-B258D983254CQ37846370-F0AE0529-67AB-4990-8EA0-D0E86F161152Q38263443-11994492-249E-414D-A88E-CCB848BAD944Q39024113-9F909718-A76B-4344-BDAA-CFDDD9FC981AQ39300430-B48DD4D8-3F65-419E-80D1-303714B02CF4Q39300914-46A6AAE5-112E-40AF-98F7-0BB03A1C05A6
P2860
The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
The HMG-CoA reductase inhibito ...... ne sterile pericarditis model.
@en
The HMG-CoA reductase inhibito ...... ne sterile pericarditis model.
@nl
type
label
The HMG-CoA reductase inhibito ...... ne sterile pericarditis model.
@en
The HMG-CoA reductase inhibito ...... ne sterile pericarditis model.
@nl
prefLabel
The HMG-CoA reductase inhibito ...... ne sterile pericarditis model.
@en
The HMG-CoA reductase inhibito ...... ne sterile pericarditis model.
@nl
P2093
P1476
The HMG-CoA reductase inhibito ...... ne sterile pericarditis model.
@en
P2093
Hideko Nakashima
Keijiro Saku
Koichiro Kumagai
P304
P356
10.1016/J.CARDIORES.2004.01.018
P577
2004-04-01T00:00:00Z